The MMEDS Act of 2023 is designed to encourage companies to move or build medical manufacturing facilities in struggling parts of the country. The main incentive is a tax break: companies that manufacture drugs or medical devices in economically distressed areas can get a credit worth 40% of their costs, including worker wages, employee benefits, and equipment expenses. There's also a tax credit for medical manufacturers who buy products and services from other businesses in these struggling zones. Essentially, the government is using tax cuts to make it more financially attractive for medical companies to invest in and hire workers in areas that need economic help.

The bill also includes a separate requirement for the Department of Health and Human Services to research how COVID-19 and past pandemics have affected older people and vulnerable populations more severely than others. This research component aims to better understand the health disparities created by these health crises so policymakers can address them in the future. Overall, the bill combines economic incentives for medical manufacturing with a focus on understanding pandemic impacts on at-risk groups.

MMEDS Act of 2023

Rubio, Marco

Medical Manufacturing, Economic Development, and Sustainability Act of 2023 or the MMEDS Act of 2023 This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical product manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical product manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical product manufacturers.. The bill also directs the Department of Health and Human Services to study the extent to which the health of aging individuals and vulnerable populations have been disproportionately harmed by the COVID-19 (i.e., coronavirus disease 2019) pandemic and prior epidemics and pandemics.